Advertisement
Finance
Subscribe to Finance

The Lead

Valeant Forecast Overshadows Strong Quarter

July 31, 2014 1:29 pm | by The Associated Press | News | Comments

The Canadian drugmaker now expects 2014 earnings to range between $7.90 and $8.10 per share, down from a forecast it made in April for $8.55 to $8.80 per share.               

Meda to Acquire Rottapharm

July 31, 2014 8:14 am | News | Comments

Meda announced today that it has entered into a definitive agreement to acquire Rottapharm/...

Sanofi Second Quarter Profit Surges

July 31, 2014 8:06 am | News | Comments

Sanofi said today its earnings soared in the second quarter thanks to lower accounting charges...

Illinois Medicaid Restricts Use of Hepatitis Drug

July 30, 2014 3:57 pm | by CARLA K. JOHNSON, AP Medical Writer | News | Comments

Facing ballooning costs for a $1,000 pill to treat hepatitis C, Illinois' Medicaid program is...

View Sample

FREE Email Newsletter

Pharma Economics - 101

July 30, 2014 3:22 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

There has always been much hand-wringing and shouting regarding the costs of new medications. Most of this comes from people outside the industry – politicians, public health advocates, and a smattering of those that just like to hear themselves talk.

McKesson Extends Pharmaceutical Distribution Agreement with CVS Caremark

July 30, 2014 10:45 am | News | Comments

McKesson Corporation today announced a three-year extension of its existing distribution agreement with CVS Caremark through June, 2019.                   

PCI Announces Definitive Agreement to Acquire Penn Pharma

July 30, 2014 8:38 am | News | Comments

Packaging Coordinators has reached a definitive agreement to acquire Penn Pharmaceutical Services Limited. Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom and operates regional offices in New Hope, Pennsylvania and Tokyo, Japan.

Advertisement

AstraZeneca to Acquire Almirall's Respiratory Disease Business

July 30, 2014 8:11 am | News | Comments

AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.

Baxter to Sell Commercial Vaccines Business to Pfizer

July 30, 2014 8:06 am | News | Comments

Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.   

Amgen Laying Off at Least 2,400

July 30, 2014 7:56 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Amgen said it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall Street expectations.           

Impax Labs Shares Slump after FDA Inspection

July 29, 2014 3:59 pm | News | Comments

Shares of Impax Labs sank Tuesday after an FDA inspection uncovered potential problems at a facility where the company will make its experimental Parkinson's disease drug Rytary.            

Fitch: Biologics Driving Revenue Gains for U.S. Pharmaceutical Companies

July 29, 2014 3:39 pm | News | Comments

Fitch Ratings expects that revenues from biologic therapies as a percentage of total pharmaceutical sales will continue to increase over the intermediate term as companies increase their prominence in their drug portfolios, according to a report published today.

Advertisement

Report: Medicare's Own Health Looking Better

July 29, 2014 8:53 am | by STEPHEN OHLEMACHER, Associated Press; RICARDO ALONSO-ZALDIVAR, Associated Press | News | Comments

Getting relief from a slowdown in health care spending, the program's giant hospital trust fund won't be exhausted until 2030, the government said Monday. That's four years later than last year's estimate.        

Pfizer's Second Quarter Profit Sinks 79% But Tops Forecasts

July 29, 2014 8:30 am | News | Comments

Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.  

$1,000 Pill Now Hepatitis C Treatment of Choice

July 29, 2014 8:26 am | by RICARDO ALONSO-ZALDIVAR, Associated Press | News | Comments

In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health. But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66B.

Corning Second Quarter Profit Falls 74%

July 29, 2014 8:21 am | News | Comments

The Corning, New York-based company said earnings fell to $169 million, or 11 cents per share, from $638 million, or 43 cents per share, in the same quarter a year ago.              

Merck Second Quarter Profit More Than Doubles

July 29, 2014 7:29 am | by The Associated Press | News | Comments

Merck has reported earnings that more than doubled in its second quarter, and topped analysts' expectations. The Whitehouse Station, New Jersey-based company said net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Advertisement

PaxVax Acquires FDA-Approved Typhoid Vaccine Vivotif

July 28, 2014 9:19 am | News | Comments

PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland.

Ortho-Clinical Diagnostics and Astute Medical to Develop Acute Kidney Injury Tests

July 28, 2014 9:06 am | News | Comments

Ortho-Clinical Diagnostics has entered into a strategic partnership with Astute Medical, under which OCD will become the exclusive commercial partner for the distribution of Astute’s NEPHROCHECK ® Test and ASTUTE140 ® Meter in certain markets in Europe and, pending FDA clearance, the United States.

Can Canadian-Style Health Care Work in Vermont?

July 28, 2014 9:01 am | Videos | Comments

In Vermont, a new health care experiment is under the microscope.                                

AbbVie Second Quarter Profit Climbs 2.8%

July 25, 2014 1:41 pm | News | Comments

AbbVie's second-quarter profit increased nearly 3 percent and beat analysts' expectations, as sales soared for the world's top-selling drug, Humira.                

Obama Wants Limits on US Company Mergers Abroad

July 25, 2014 8:32 am | News | Comments

Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.      

Ten Cities Where the Drug Business Thrives

July 24, 2014 1:54 pm | News | Comments

They've got money, connections and hordes of eager college students. Ten U.S. cities head a new list of best places to develop and distribute drugs...of the legal kind, that is.  The 2014 JLL Global Life Sciences Cluster Report analyzes the top cities where science and pharmaceutical innovation converge.

BMS Second Quarter Net Drops on Lower Drug Sales, Charges

July 24, 2014 8:15 am | News | Comments

Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.

Lilly Second Quarter Profit Falls 39%

July 24, 2014 7:31 am | by The Associated Press | News | Comments

Eli Lilly and Co. (LLY) on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations. The Indianapolis-based company said earnings declined to $733.5 million, or 68 cents per share, from $1.21 billion, or $1.11 per share, in the same quarter a year earlier.

Roche Posts Seven Percent Profit Drop

July 24, 2014 2:29 am | by The Associated Press | News | Comments

Swiss drugmaker Roche Holding AG on Thursday posted a net profit drop of 7 percent compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units.          

Biogen Idec Second Quarter 2014 Revenues Increase 40%

July 23, 2014 9:18 am | News | Comments

Biogen Idec today reported second quarter 2014 results, including revenue of $2.4 billion, a 40% increase compared to the second quarter of 2013. Second quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.49, an increase of 52% over the second quarter of 2013.

GSK's CEO and CFO Discuss the Company's Second Quarter Results

July 23, 2014 9:13 am | Videos | Comments

GSK CEO Sir Andrew Witty and CFO Simon Dingemans on the group’s Q2 2014 results and strategy update.                         

Shire Enters Strategic Licensing and Collaboration Agreement with ArmaGen

July 23, 2014 8:02 am | News | Comments

Shire and ArmaGen announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading